TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03392818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The measured distance
Description: To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of Fiberoptic bronchoscope.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: formula
Description: Calculate the depth of intubation according to the formula of 0.1977\* patient's height - 4.2423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope
Description: The intubation of Uniblocker under the guidance of Fiberoptic bronchoscope
Study: NCT03872856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP-ICAN
Description: One of two home blood pressure monitor devices will be used.~1. Omron 7 Series Wrist cuff~2. Omron 10 Series Upper Arm cuff
Study: NCT02205242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynaport®
Description: Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dynaport®
Description: Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04146935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab Injection [Crysvita]
Description: Burosumab/Crysvita SC injection monthly
Study: NCT03207633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive trans-magnetic stimulation (rTMS) on DLPFC
Description: Repetitive trans-magnetic stimulation (rTMS) on DLPFC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive trans-magnetic stimulation (rTMS) on OFC
Description: Repetitive trans-magnetic stimulation (rTMS) on OFC

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive trans-magnetic stimulation (rTMS)
Description: Sham repetitive trans-magnetic stimulation (rTMS)
Study: NCT03559933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEPNS System
Description: PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
Study: NCT02800980

Intervention type: PROCEDURE
Intervention: Drainage and sclerotherapy.
Description: Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.

Intervention type: PROCEDURE
Intervention: Drainage alone.
Description: Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
Study: NCT03625336

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: An MRI will be obtained utilizing 3 different MRI sequences
Study: NCT01088620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
Study: NCT02209896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Reprieve system
Description: BlueWind Medical neurostimulator for the treatment of neuropathic pain
Study: NCT02083406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 prototype formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg OZ439 prototype formulation 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960mg PQP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960mg PQP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 960mg PQP
Study: NCT02930928

Intervention type: OTHER
Intervention: Accuracy of weight estimation
Description: Computer based comparison
Study: NCT05151809

Intervention type: OTHER
Intervention: Clinical information
Description: The investigators will recruit PBC patients and collect important clinical information and laboratory investigation, together with biological samples.
Study: NCT05297188

Intervention type: DEVICE
Intervention: ergonomic sleep mask
Description: Ergonomic sleep mask; It is a material that covers the eye and ear completely and can be adjusted according to the patient, can be washed and reused at 30 degrees after use, 95% cotton, 5% polyester structure and 100% light proof properties.
Study: NCT02566629

Intervention type: OTHER
Intervention: collect faeces from participants
Description: analyze the fecal microbiota community using 16S rDNA detection technique

Intervention type: OTHER
Intervention: collect faeces from participants
Description: analyze the fecal microbiota community using 16S rDNA detection technique

Intervention type: OTHER
Intervention: collect faeces from participants
Description: analyze the fecal microbiota community using 16S rDNA detection technique
Study: NCT03107741

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Exercise
Description: Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
Study: NCT03796026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant 40 mg
Description: Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant 40 mg
Description: Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
Study: NCT03470402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RealRisks
Description: RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BNAV
Description: BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iNYP
Description: Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iNYP
Description: Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Educational Material
Description: Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Educational Material
Description: Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-Risk Message
Description: Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Risk Message
Description: Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
Study: NCT00130611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BNP measurement
Study: NCT03220620

Intervention type: OTHER
Intervention: GDT
Description: individualized fluid therapy
Study: NCT02406586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate
Description: Salsalate 750 mg
Study: NCT00130611

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clinical examination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination
Study: NCT01324362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 100mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 250mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 500mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 100/50mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC 250/50mcg
Description: Twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC500/50mcg
Description: Twice daily dosing
Study: NCT00064792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin Susp.
Description: During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OraPlus
Description: During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
Study: NCT00682955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulphate
Description: 20 mg per day, Zinc Sulphate tablet has been given to subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Sulphate
Description: 20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
Study: NCT02406586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol 3.125 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet
Study: NCT00177255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22.
Study: NCT03991429

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous functional MRI and urodynamic studies
Description: Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous functional MRI and urodynamic studies
Description: Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous functional MRI and urodynamic studies
Description: Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
Study: NCT02406586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Description: 24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
Study: NCT03991429

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
Study: NCT02406586

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intralipid 20%
Description: 24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralipid 20%
Description: 24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
Study: NCT02702115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-318
Description: A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-318
Description: A single dose of each of the three components of SB-318 \[zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)\] administered via intravenous (IV) infusion.
Study: NCT03991429

Intervention type: OTHER
Intervention: Post Void Residual (PVR), Uroflow and Bladder Diary
Description: Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.

Intervention type: OTHER
Intervention: Post Void Residual (PVR), Uroflow and Bladder Diary
Description: Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.

Intervention type: OTHER
Intervention: Post Void Residual (PVR), Uroflow and Bladder Diary
Description: Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinalysis
Description: Urine sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinalysis
Description: Urine sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinalysis
Description: Urine sample
Study: NCT00883441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide treated curtains and insecticide treated covers
Description: The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide treated curtains and insecticide treated covers
Description: The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
Study: NCT03976206

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Very small embryonic-like stem cell
Description: We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Very small embryonic-like stem cell
Description: We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Very small embryonic-like stem cell
Description: We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
Study: NCT04038450

Intervention type: OTHER
Intervention: No intervention
Description: No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.

Intervention type: OTHER
Intervention: No intervention
Description: No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
Study: NCT01195324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Warfarin
Description: Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Warfarin
Description: Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
Study: NCT01973413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs)
Description: The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim Insulin Pump
Description: FDA, market-approved insulin pump.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tandem t:slim Insulin Pump
Description: FDA, market-approved insulin pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum sensor
Description: FDA, market-approved continuous glucose monitor (CGM)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dexcom G4 Platinum sensor
Description: FDA, market-approved continuous glucose monitor (CGM)
Study: NCT01189981

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: One health conversation at baseline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth intervention
Description: SMS based encouragements to intensive exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth intervention
Description: SMS based encouragements to intensive exercise